Table 1.
Clinical and inflammatory characteristics of severe asthma non-, ex-, and current-smokers present in the Urinary 8-iso-PGF2α subset.
Table 2.
Clinical and inflammatory characteristics of severe asthma non-, ex-, and current-smokers present in the induced sputum-transcriptomic subset.
Table 3.
Clinical and inflammatory characteristics of severe asthma non-, ex-, and current-smokers present in the bronchial biopsy-transcriptomic subset.
Table 4.
Clinical and inflammatory characteristics of severe asthma non-, ex-, and current-smokers present in the bronchial brushing-transcriptomic subset.
Fig 1.
(A) Comparison of 8-iso-PGF2α in urine between SAn and SAs/ex. (B) Comparison of urinary 8-iso-PGF2α between severe asthma smoking subgroups. CSA: current smokers with severe asthma; ESA: ex-smokers with severe asthma; NSA: non smokers with severe asthma; SAn: Severe Asthma non smokers; SAs/ex: Severe Asthma smokers/ex-smokers.
Table 5.
Comparison of pro-/anti-oxidant enzyme mRNA expression in induced sputum, bronchial biopsies and bronchial brushings between severe asthma cohorts.
Fig 2.
Scatter plot of the relationship between NOS2 expression in bronchial brushing and FeNO.
NOS2 expression in bronchial brushing were strongly correlated to FeNO. Kendall’s Tau = 0.535, p< 0.001, (n = 62). FeNO (ppb) were log2-transformed. SAn: Severe Asthma non smokers; SAs/ex: Severe Asthma smokers/ex-smokers.